• Explore /
  • Poster
  • / Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.

Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.

Abstract Poster

Authors

null

David Andrew Sallman

Moffitt Cancer Center, Tampa, FL

David Andrew Sallman , Monzr M. Al Malki , Adam Steven Asch , Eunice S. Wang , Joseph G. Jurcic , Terrence J. Bradley , Ian W. Flinn , Daniel Aaron Pollyea , Suman Kambhampati , Tiffany N. Tanaka , Joshua F. Zeidner , Deepa Jeyakumar , Lin Gu , Anderson Tan , Mark Chao , Carol Elaine O'Hear , Indu Lal , Paresh Vyas , Naval Guastad Daver , Guillermo Garcia-Manero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myelodysplastic Syndromes (MDS)

Clinical Trial Registration Number

NCT03248479

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7017)

DOI

10.1200/JCO.2022.40.16_suppl.7017

Abstract #

7017

Poster Bd #

248

Abstract Disclosures

Similar Posters

First Author: James Yuhtyng Chen

First Author: David Andrew Sallman

First Author: Naval Guastad Daver

First Author: Veronica Guerra